The effects of IgM-enriched immunoglobulin preparations in patients with severe sepsis [ISRCTN28863830] by Tugrul, Simru et al.
Available online http://ccforum.com/content/6/4/357
Research
The effects of IgM-enriched immunoglobulin preparations in
patients with severe sepsis [ISRCTN28863830]
Simru Tugrul1, Perihan Ergin Ozcan1, Ozkan Akinci1, Yalcin Seyhun2, Atahan Cagatay3, 
Nahit Cakar4 and Figen Esen4
1Registrar, Anesthesiology Department, Medical Faculty, Istanbul University, Turkey
2Registrar, Medical Biology Department, Medical Faculty, Istanbul University, Turkey
3Registrar, Clinical Bacteriology and Infectious Diseases Department, Medical Faculty, Istanbul University, Turkey
4Consultant, Anesthesiology Department, Medical Faculty, Istanbul University, Turkey
Correspondence: Simru Tugrul, mtugrul@isbank.net.tr
Introduction
Despite developing therapeutic strategies and new antibiotic
regimens, mortality of sepsis and septic shock has actually
remained at a level of about 35–50%. Novel anti-inflammatory
treatment regimens such as anti-tumor necrosis factor, anti-
platelet-activating factor, anti-interleukin-1, anti-endotoxin,
anti-bradykinin, inhibitors of nitric oxide synthase and steroids
have also yielded disappointing results until now [1,2].
APACHE II = acute physiological and chronic health evaluation II; ivIg = intravenous immunoglobulin; PCT = procalcitonin; SOFA = sequential
organ failure assessment.
Abstract
Introduction In this prospective, randomized controlled study, we aimed to evaluate the effect of IgM-
enriched immunoglobulin treatment on progression of organ failure and septic shock in patients with
severe sepsis.
Materials and methods Forty-two patients with severe sepsis were enrolled in the study. Patients in
the study group (n = 21) received an intravenous immunoglobulin preparation (Pentaglobin®) in
addition to standard therapy. Pentaglobin® therapy was commenced on the day of diagnosis of severe
sepsis: 5 ml/kg per day Pentaglobin® (38 g/l IgG, 6 g/l IgM, and 6 g/l IgA) was infused over 6 hours
and repeated for 3 consecutive days. Patients in the control group (n = 18) received standard sepsis
therapy, but no immunoglobulin administration. Blood samples for procalcitonin (PCT) measurements
were taken daily for 8 days. Severity of critical illness and development of organ failure were assessed
by obtaining daily acute physiological and chronic health evaluation (APACHE) II and sequential organ
failure assessment (SOFA) scores.
Results and discussion Procalcitonin levels showed a statistically significant decrease in the
Pentaglobin® group (P < 0.001); however, an improvement in SOFA scores could not be
demonstrated. Procalcitonin levels and SOFA scores did not change significantly in the control group.
Septic shock incidence (38% versus 57%) and 28-day mortality rate (23.8% versus 33.3%) were
found to be similar between the Pentaglobin® and control groups. The evaluation of serial APACHE II
scores did not demonstrate a difference between Pentaglobin® and control groups either.
Conclusion Present data could not demonstrate any beneficial effects of polyclonal immunoglobulin
preparation Pentaglobin® on organ morbidity, septic shock incidence and mortality rate in patients with
severe sepsis.
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Systemic inflammatory response syndrome and sepsis are
diseases of the immune system rather than simple effects of a
causative agent. An immunotherapeutic approach that acts
through neutralization of endotoxin and various bacterial prod-
ucts by passive administration of intravenous immunoglobulin
(ivIg) seems to be promising in clinical practice, rather than
target one mediator of the inflammatory cascade. Besides the
effect of immunoglobulin substitution in a case of deficiency,
several other mechanisms, such as neutralizing endotoxins
and exotoxins, scavenging active complement components,
as well as lipopolysaccharides, stimulating opsonic and bac-
tericidal activity in serum, reducing pro-inflammatory media-
tors, and increasing anti-inflammatory mediators, have been
postulated for the possible beneficial effects of ivIg in septic
patients.
It has been previously shown that commercial ivIgG products
contained antibodies against Gram-negative and Gram-positive
bacteria, often encountered in the intensive care unit [3]. In a
recent study, Trautmann et al. [4] showed that antibodies
against lipopolysaccharides of Escherichia coli, Pseudomonas
aeruginosa and Klebsiella spp. are much more concentrated
in human IgM fraction.
In this prospective, randomized controlled study, we aimed to
evaluate the effect of IgM-enriched immunoglobulin treatment
on progression of organ failure and septic shock in patients
with severe sepsis.
Materials and methods
Patients
After approval by the faculty ethics committee, patients with
severe sepsis (temperature >38°C or <36°C, heart rate
>90 beats/min, respiratory rate >20/min or PaCO2
<32 mmHg, white blood cell count >12,000/mm3 or
<4000/mm3, documented infection and dysfunction of an
organ or hypotension) were enrolled in the study.
Study design
Patients were randomly allocated to the study groups accord-
ing to the numerical order of a computer-generated random-
ization list. Patients in the study group (n = 21) received ivIg
preparation in addition to standard sepsis therapy. Polyclonal
ivIg treatment (Pentaglobin®, Biotest Pharma GmbH, Drei-
eich, Germany) was started on the day of diagnosis of severe
sepsis: 5 ml/kg per day Pentaglobin® (38 g/l IgG, 6 g/l IgM
and 6 g/l IgA) was infused intravenously over a period of
6 hours and repeated for 3 consecutive days. Patients in the
control group (n = 18) received standard sepsis therapy, but
no immunoglobulin administration.
Electrocardiogram, invasive arterial blood pressure and
central venous pressure were monitored continuously
(Horizon XL; Mennen Medical, Rehovot, Israel). The aim was
to achieve a central venous pressure of 8–12 mmHg.
Dopamine, dobutamine, epinephrine and/or norepinephrine
were used to treat hypoperfusion that was unresponsive to
volume resuscitation. Oliguria and fluid overload were treated
by hemofiltration, if adequate urine flow could not be obtained
by medical therapy. Steroids were not used in any of the
patients. Septic shock was diagnosed when severe sepsis
was associated with hypotension (systolic blood pressure
<90 mmHg or a reduction of >40 mmHg from baseline, in
the absence of other cause for hypotension) despite ade-
quate fluid resuscitation. Pulmonary artery catheterization was
performed following the diagnosis of septic shock.
Measurements
Blood samples for procalcitonin (PCT) measurements were
taken daily for 8 days following study admission. Samples
were obtained from an arterial catheter every morning and the
samples were processed by the same person in the labora-
tory of the Medical Biology Department. PCT was determined
with an immunoluminometric assay, allowing quantitative
measurement of a wide range of PCT concentrations
(B.R.A.H.M.S. Diagnostica GmbH, Berlin, Germany).
Severity of critical illness was assessed by obtaining daily
acute physiological and chronic health evaluation score
(APACHE II). Sequential organ failure assessment (SOFA)
score was used to assess the development of organ failure,
and in an attempt to describe the degree of organ failure over
time in individual septic patients. Duration of mechanical ven-
tilation, length of stay in the intensive care unit, septic shock
incidence and 28-day mortality rate were also recorded.
Appropriate microbial samples were obtained before pre-
scribing any prophylactic and pre-emptive medication, and if
this was not possible then the probable causative agents
were considered and therapy was administered accordingly.
All isolated bacteria were identified and antimicrobial suscep-
tibilities of isolates were determined by the disk diffusion
method described in NCCLS M2-A6 and M100-S8 [5,6]. In
these patients with sepsis, all samples, especially blood cul-
tures, should be obtained as soon as possible and before any
changes are made in antimicrobial therapy.
Statistical analysis
Data are presented as mean ± SD or median (range) for data
that were not normally distributed. Admission data are
assessed using an unpaired t-test. Demographic and
outcome data were examined on the basis of intention-to-
treat analysis. Mortality rate, septic shock incidence and
gender were compared using Fisher’s exact test. The
Mann–Whitney U-test was used for comparison of quantita-
tive variables between the groups. PCT values, SOFA and
APACHE II scores were not normally distributed; these were
analyzed with Friedman analysis of variance on ranks. In case
of statistical significance, intragroup analyses were performed
using the Wilcoxon test. A P value less than 0.05 was con-
sidered significant. Data analyses and statistics were per-
formed using SPSS for Windows v. 10.0.1.Results
Forty-two patients were randomly allocated into two groups.
Three patients from the control group were excluded because
of technical problems during laboratory analysis. Demographic
data and clinical characteristics of the patients are presented
in Table 1. Both groups were comparable with respect to their
admission APACHE II and SOFA scores. Infection sources
and causative organisms obtained are shown in Table 2.
Thirteen patients (72%) in the control group and 14 patients
(67%) in the Pentaglobin® group had sepsis resulting from
infection with Gram-negative microorganisms. Mortality rates
of those sub-groups of patients were 23% in the control
group and 14% in the Pentaglobin® group (P = 0.6).
PCT levels showed a statistically significant decrease in the
Pentaglobin® group (P < 0.001); however, an improvement in
SOFA scores could not be demonstrated. PCT levels and
SOFA scores did not change significantly in the control
group (Table 3). Daily PCT levels and SOFA scores of both
groups are shown in Figs 1 and 2.
APACHE II scores showed a statistically significant decrease
in the Pentaglobin® and control groups (P < 0.001 in both
groups). PCT levels, SOFA and APACHE II scores did not
demonstrate statistically significant differences between the
groups on each evaluation day.
Duration of mechanical ventilation, length of intensive care
stay, septic shock incidence and 28-day mortality rate were
found to be similar between the groups (Table 4).
Discussion
In the present study, the use of IgM-enriched and IgA-
enriched IgG preparation in addition to standard sepsis
therapy could not produce an improvement in any of the
outcome measures of patients with severe sepsis. The only
encouraging observation was the reduction in PCT levels
obtained with Pentaglobin® administration.
In the previous studies [4,7] specific IgM and IgG antibodies
against lipopolysaccharides of Escherichia coli strains, Kleb-
siella pneumoniae, Pseudomonas aeruginosa, α-haemolysin
of Staphylococcus aureus, and against surface proteins of
oxacillin-resistant S. aureus and vancomycin-resistant strep-
tococci were detected in Pentaglobin® solution. When using
in vitro cell cultures, Pentaglobin® preparation produced the
highest inhibition of tumor necrosis factor α release when
added to the medium with lipopolysaccharide [8]. Rieben et
al. [9] showed that IgM enrichment of ivIg preparations leads
to an enhanced complement-inhibitory capacity both in vitro
and in vivo as compared with pure ivIgG.
Monoclonal (IgG) and polyclonal (IgGMA) immunoglobulin
solutions have previously been applied to different groups of
intensive care patients. Both IgG and IgGMA have been used
prophylactically in high-risk patients after cardiac surgery and
resulted in an improvement in infectious morbidity and in a
reduction in mortality rate [10–12]. However, consistent
reductions in mortality could not be demonstrated in placebo-
controlled trials performed in sepsis or septic shock. IgG was
applied to 653 sepsis patients having an APACHE II score
higher than 20; a moderate improvement was obtained in
severity of sepsis, but the mortality rate could not be reduced
[13]. De Simone et al. [14] used IgG solution in patients with
severe sepsis and obtained reductions in hospitalization and
number of days on antibiotics, as well as in the number of
positive cultures; however, the mortality rate (75% control
versus 58% ivIgG) was unchanged. Similarly, Just et al. [15]
(41% control versus 44% ivIgGMA), Jesdinsky et al. [16]
(41% control versus 46% ivIgG, ivIgGMA) and Vogel [17]
(44% control versus 24% ivIgGMA) were also not able to
demonstrate reductions in mortality rate by IgGMA applica-
tion to different intensive care patients with sepsis.
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Table 1
Clinical characteristics of patients on admission
Pentaglobin® Control 
Characteristic group (n = 21) group (n = 21) P
Age (range) 42.0 ± 18 (10–72) 49.3 ± 20.6 (20–76) 0.23
Gender (F/M) 9/12 11/10 0.75
APACHE II 10.5 ± 4.6 14.0 ± 8.5 0.10
SOFA 5.0 ± 2.7 5.7 ± 4.0 0.50
GCS 14.2 ± 2.1 12.9 ± 4.0 0.20
Values are expressed as mean ± SD. APACHE II, acute physiological
and chronic health evaluation; F/M, female/male; GCS, Glasgow
Coma Scale; SOFA, sequential organ failure assessment.
Table 2
Sources of infection and causative organisms
Criterion Pentaglobin® group Control group
Sources of  Abdominal sepsis 11 (52.4) Abdominal sepsis 9 (42.8)
infection Urosepsis 1 (4.8) Urosepsis 2 (9.5)
Pneumonia 5 (23.8) Pneumonia 9 (42.8)
CNS infection 3 (14) Pericarditis 1 (4.7)
Endocarditis 1 (4.8)
Causative  P. aeruginosa 5 (23.8) P. aeruginosa 5 (23.8)
organisms MRSA 9 (42.8) MRSA 5 (23.8)
Acinetobacter sp. 1 (4.8) Acinetobacter sp. 4 (19)
K. pneumoniae 1 (4.8) K. pneumoniae 1 (4.7)
Enterobacter sp. 1 (4.8) E. coli 1 (4.7)
S. maltophilia 1 (4.8) Undetermined 5 (23.8)
Undetermined 3 (14)
Values are expresed as n (%). Pentaglobin® group (n = 21); control
group (n = 21). CNS, central nervous system; MRSA, methicillin-
resistant Staphylococcus aureus; E. coli, Escherichia coli; K.
pneumoniae, Klebsiella pneumoniae; P. aeruginosa, Pseudomonas
aeruginosa; S. maltophilia, Stenotrophomonas maltophilia.Critical Care    August 2002 Vol 6 No 4 Tugrul et al.
Figure 1
Procalcitonin plasma concentrations of patients in Pentaglobin® and
control groups. Indicated are median (inner line), 25/75 percentiles
(box) and 10/90 percentiles (whisker) obtained during an 8-day
observation period. *P < 0.05, **P < 0.01 when compared to Day 1.
Figure 2
Sequential organ failure assessment (SOFA) scores of patients in
Pentaglobin® and control groups. Indicated are median (inner line),
25/75 percentiles (box) and 10/90 percentiles (whisker) obtained
during an 8-day observation period.
Table 3
Procalcitonin levels, SOFA and APACHE II scores
Measurement Day 1 Day 2 Day 3 Day 4 Day 5 Day 6 Day 7 Day 8 ANOVA
PCT (ng/mL)
Pentaglobin® 5.5 3.5* 3.5** 3.05* 2.6* 2.45 2.0* 1.45** <0.001
(0.9–72.0) (0.9–65.0) (0.9–39.0) (0.9–23.0) (0.8–11.0) (0.6–11.0) (0.6–11.0) (0.6–14.3)
Control 4.0 3.14 3.2 2.65 3.15 4.0 4.0 4.0 0.8
(0.4–194.0) (0.4–72.0) (0.2–34.0) (0.6–18.0) (0.5–14.0) (0.6–21.6) (0.3–117.0) (0.5–185.0)
SOFA
Pentaglobin® 5.0 6.0 6.0 5.0 4.0 4.0 3.5 4.0 0.2
(1.0–10.0) (1.0–11.0) (0–12) (0–16) (0.0–16.0) (0–16) (0.0–15.0) (0–14)
Control 4.5 5.5 5.0 5.0 4.5 5.0 4.0 6.0 0.3
(1.0–12.0) (1.0–15.0) (2–15) (2–12) (1.0–10.0) (1–11) (1.0–11.0) (0–10)
APACHE II
Pentaglobin® 15.0 14.0 14.0 13.0 11.0 11.5* 12.5 8.0** <0.001
(9–24) (8.0–28.0) (7–24) (7–30) (5.0–30.0) (5.0–30.0) (5.0–30.0) (5–30)
Control 16.0 15.5 16.0 15.0 11.5** 11.0** 11.0** 11.0** <0.001
(3–27) (5.0–27.0) (5–24) (4–22) (3.0–21.0) (1.0–27.0) (1.0–21.0) (1–16)
Values are expressed as median (range). ANOVA, analysis of variance; APACHE II, acute physiological and chronic health evaluation; PCT,
procalcitonin; SOFA, sequential organ failure assessment. *P < 0.05, **P < 0.01 when compared to Day 1.On the other hand, impressive improvement in outcome for
septic patients was reported in certain investigations using ivIg
preparations [18,19]. In a study performed by Dominioni et al.
[18], the mortality rate was reduced by administration of the
IgG solution from 67% to 38% in postoperative septic patients
having a sepsis score higher than 20. Schedel et al. [19]
reported a statistically significant decrease in the APACHE II
score beyond the fifth day after inclusion, as well as a decrease
in the 6-week mortality rate (1/27 in the Pentaglobin® group
versus 9/28 in the control group) in septic shock patients
receiving Pentaglobin® treatment. Serum concentrations of
endotoxin-equivalent were also found to be decreased signifi-
cantly within 24 hours after inclusion of the patients in the study
in patients treated with Pentaglobin®. The Cochrane group
analyzed 23 controlled clinical studies published between
1966 and 1999 and found that sepsis-related mortality was
significantly reduced only in patients who received polyclonal
ivIg in contrast to treatment with monoclonal antibodies and
anti-cytokines in sepsis and septic shock [20].
Our results could not make a clear-cut contribution to the
conflicting data obtained from trials studying the effects of
the different types of immunoglobulin preparations in septic
patients. As well as the use of different antibiotics, other
treatment strategies, such as the use of catecholamines, cor-
ticosteroids or hemofiltration have the potential to interact
with the immune system and, therefore, with the response of
the patients. If we examine possible explanations for inconsis-
tency of the literature, the dosage and application schedule
as well as the timing of immunomodulatory therapy should
also be taken into consideration. Almost all investigators
applied a total amount of approximately 1 l Pentaglobin® 5%
during 3 consecutive days in previous studies. The stage of
the disease at which immunoglobulin substitution was per-
formed might be an important determinant of the response of
the patients. The most striking data about the beneficial
effects of polyclonal immunoglobulin were presented by
Schedel et al. [19] in septic shock patients. Dominioni et al.
[18], also reported impressive mortality reduction with the
IgG preparation in septic patients with a sepsis score higher
than 20.
It is now well known that systemic inflammatory response
syndrome is the result of the imbalance between proinflam-
matory and anti-inflammatory forces. The compensatory anti-
inflammatory response is assumed to lead to an increased
susceptibility to infection or anergy, whereas systemic over-
flow of the proinflammatory system may lead to apoptosis,
organ dysfunction, and thus septic shock. The anti-inflamma-
tory potential of Pentaglobin® may not show clear benefits, or
may even be harmful, in cases or at disease stages in which
proinflammatory forces are not dominant. According to this
paradigm, a more precise understanding of the laboratory
and clinical information of the immune status of patients will
help with administering the right drug at the right time for the
right patient.
It was suggested that a single therapeutic method of
immunoglobulin substitution in the therapy of this complex
syndrome might accomplish the goal of improvement in mor-
bidity, instead of expecting a magic approach to reducing the
mortality rate in sepsis. In this study, the SOFA score was
used to describe the damage to the different organ systems,
as well as the impact of the therapy on the progression of
organ dysfunction. With regard to the SOFA scores, which
did not demonstrate an improvement in organ morbidity
throughout the 8-day follow-up period, this proposal was not
supported by our findings.
PCT is a pro-hormone that shows elevated plasma levels in
severe bacterial, fungal and parasitic infections, as well as in
sepsis and multiorgan failure. It has been used not only in the
diagnosis of sepsis but also in treatment of the clinical course
of the disease [21,22]. In contrast to the control group, this
marker demonstrated a consistent decline in patients treated
with Pentaglobin® preparation. However, the decline in PCT
levels did not correspond with the clinical course of severe
sepsis, which was reflected in unchanged SOFA scores
throughout the study. The evaluation of serial APACHE II
scores also did not demonstrate a difference between the
Pentaglobin® and control groups.
In our study there are some limitations that should be noted.
Restricting the investigation period to only 8 days might have
hampered the detection of an improvement in SOFA scores
of the patients. We suggest that extending the duration of
data collection might allow the change in PCT levels to be
accompanied by an improvement of the severity of organ dys-
function. The increase in PCT levels on days 6–8 could pos-
sibly reflect a septic relapse in some of the patients in the
control group. Because cytokine levels were not measured in
the present study, we could not comment on the possible
role of Pentaglobin® in the prevention of a similar relapse in
the treatment group. Our study was performed in a relatively
small group of patients with severe sepsis. Increasing the
number of patients could confirm a change in the severity of
organ dysfunction, the incidence of septic shock and mortal-
ity rate as a result of using Pentaglobin®.
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Table 4
Clinical outcome of patients
Pentaglobin® Control 
Criterion group group P
Septic shock incidence (%) 8/21 (38) 12/21 (57) 0.35
Duration of mechanical  20 (2–58) 19 (2–76) 0.60
ventilation (days)
ICU length of stay (days) 29 (3–89) 22 (3–85) 0.35
28-day mortality (%) 5/21 (23.8) 7/21 (33.3) 0.70
Values are expresed as median (range). Pentaglobin® group (n = 21);
control group (n = 21). ICU, intensive care unit.Conclusion
In conclusion, our data could not demonstrate any beneficial
effects of the polyclonal immunoglobulin preparation Penta-
globin® on organ morbidity, septic shock incidence and mor-
tality rate in patients with severe sepsis. We believe that
further investigations should focus on laboratory and clinical
measures to identify and monitor patients who might benefit
from specific immunomodulatory therapies.
Competing interests
None declared.
References
1. Calandra T, Baumgartner JD: Anti-endotoxin therapy. In Clinical
Trials for the Treatment of Sepsis (Update in Intensive Care and
Emergency Medicine 19). Edited by Sibbald WJ, Vincent JL.
Berlin, Heidelberg: Springer-Verlag, 1995: 237-250.
2. Werdan K, Pilz G: Supplemental immunoglobulins in sepsis: a
critical appraisal. Clin Exp Immunol 1996, 104(suppl):S83-S90.
3. Lamari F, Anastassiou ED, Tsegenidis T, Dimitracopoulos G, Kara-
manos NK: An enzyme immunoassay to determine the levels
of specific antibodies toward bacterial surface antigens in
human immuno-globulin preparations and blood serum. J
Pharm Biomed Anal 1999, 20:913-920.
4. Trautmann M, Held TK, Susa M, Karajan MA, Wulf A, Cross AS,
Marre R: Bacterial lipopolysaccharide-specific antibodies in
commercial human immunoglobulin preparations: superior
antibody content of an IgM-enriched product. Clin Exp
Immunol 1998, 111:81-90.
5. National Committee for Clinical Laboratory Standards: Perfor-
mance Standards for Antimicrobial Susceptibility Tests, 6th
edition. Approved Standards NCCLS Document M2-A6. Vil-
lanova, PA: NCCLS; 1997.
6. National Committee for Clinical Laboratory Standards: Perfor-
mance Standards for Antimicrobial Susceptibility Testing, 10th
Informational Supplement. NCCLS Document M100-S10. Vil-
lanova, PA: NCCLS; 2000.
7. Lissner R, Struff WG, Autenrieth IB, Woodcock BG, Karch H:
Efficacy and potential clinical applications of Pentaglobin, an
IgM-enriched immunoglobulin concentrate suitable for intra-
venous infusion. Eur J Surg 1999, 584(suppl):S17-S25.
8. Trautmann M, Karajan MA, Susa M: Intravenous immunoglobu-
lins inhibit LPS-induced TNF alpha release from human
monocytic cells. In  Congress Proceedings, 4th International
Symposium on the Immune Consequences of Trauma, Shock
and Sepsis. Edited by Faist E. Bologna, Italy: Monduzzi Editore;
1997:775-779.
9. Rieben R, Roos A, Muizert CT, Tinguely C, Gerritson AF, Daha
MR:  Immunoglobulin M-enriched human intravenous
immunoglobulin prevents complement activation in vitro and
in vivo in a rat model of acute inflammation. Blood 1999, 93:
942-951.
10. Pilz G, Kreuzer E, Kaab S, Appel R, Werdan K: Early sepsis
treatment with immunoglobulins after cardiac surgery in
score-identified post-cardiac patients at high risk for sepsis.
Chest 1994, 105:76-82.
11. Pilz G, Appel R, Kreuzer E, Werdan K: Comparison of early IgM-
enriched immunoglobulin versus polyvalent IgG administra-
tion in score-identified post-cardiac surgical patients at high
risk for sepsis. Chest 1997, 111:419-426.
12. Kress HG, Scheidewig C, Schmitt H, Silber RE: Reduced inci-
dence of postoperative infections following intravenous appli-
cation of an IgA and IgM-enriched immunoglobulin
preparation in anergic patients undergoing cardiac surgery.
Crit Care Med 1999, 27:1281-1287.
13. Werdan K, Pilz G, and the SBITS Study Group: Polyvalent
immune globulins. Shock 1997, 7(suppl):A5/1918.
14. De Simone C, Delogu G, Corbetta G: Intravenous immunoglob-
ulins in association with antibiotics: a therapeutic trial in
septic intensive care unit patients. Crit Care Med 1988, 16:23-
26.
15. Just HM, Metzger M, Vogel W, Pelka RB: Einfluss einer adjuvan-
ten Immunoglobulin-Therapie auf Infektionen bei Patienten
einer operativen Intensiv-Therapie-Station: Ergebnisse einer
randomisierten kontrollierten Studie. Klin Wochenschr 1986,
64:245-256.
16. Jesdinsky HJ, Tempel G, Castrup HJ, Seifert J: Cooperative
group of additional immunoglobulin therapy in severe bacter-
ial infections: results of a multicenter randomized controlled
trial in cases of diffuse fibrinopurulent peritonitis. Klin
Wochenschr 1987, 65:1132-1138.
17. Vogel F: Bewertung der intravenösen IgM-Therapie bei schw-
eren nosokomialen Infektionen (Ergebnis einer kontrollierten
randomisierten Studie). In Klinisch angewandte Immunologie-
Sepsis Therapie mit IgM-angereichertem Immunoglobulin. Edited
by Deicher H, Schoppe W. Berlin: Springer-Verlag; 1988:30-41.
18. Dominioni L, Dionigi R, Zanello M, Chiaranda M, Dionigi R,
Acquarolo A, Ballbio A, Sguotti Cl: Effects of high dose IgG on
survival of surgical patients with sepsis scores of 20 or
greater. Arch Surg 1991, 126:236-240.
19. Schedel I, Dreikhausen U, Nentwig B, Hockenschnieder M, Rauth-
mann D, Balikcioglu S, Coldewey R, Deicher H: Treatment of
gram-negative septic shock with an immunoglobulin prepara-
tion: A prospective, randomized clinical trial. Crit Care Med
1991, 19:1104-1113.
20. Alejandria MM, Lansang MA, Dans LF, Mantaring JBV: Intra-
venous immunoglobulin for treating sepsis and septic shock
(Cochrane Review). In The Cochrane Library. Issue 2. Oxford:
Update Software Ltd; 2002:4.
21. Volk HD, Reinke P, Döcke WD: Immunologic monitoring of the
inflammatory process: Which variables? When to assess? Eur
J Surg 1999, 584(suppl):S70-S72.
22. Reith HB, Mittelkötter U, Debus ES, Kussner C, Thiede A: Procal-
citonin in early detection of postoperative complications. Dig
Surg 1998, 15:260-265.
Critical Care    August 2002 Vol 6 No 4 Tugrul et al.
Key messages
• The aim of this prospective study is to evaluate the
effect of IgM-enriched immunoglobulin treatment on
progression of organ failure and septic shock in
patients with severe sepsis.
• Reduction in PCT levels observed with 
Pentaglobin® administration was a striking observation
of the study.
• Serial SOFA and APACHE II scores did not reveal 
significant differences between the groups.
• The decline in PCT levels did not correspond with the
clinical course of severe sepsis in the 
Pentaglobin® group.
• Present data could not demonstrate any beneficial
effects of polyclonal immunoglobulin preparation on
organ morbidity, septic shock incidence and mortality
rate in patients with severe sepsis.